Send PM
Followers 90
Posts 1504
Boards Moderated 0
Alias Born 11/22/2017

Re: None

Friday, 03/12/2021 8:29:38 PM

Friday, March 12, 2021 8:29:38 PM

Post# of 539692
UCLA Brain Tumor Virtual Conference (part 2)

Date Time: Mar 12, 2021 10:00 AM Pacific Time (US and Canada)

Here are a few questions answered by Nghiemphu, Phioanh Leia.

Anonymous Attendee 10:23 PM
Can you discuss where you are with DCVax? Wasn't this invented and developed at UCLA?

Nghiemphu, Phioanh [Leia] M.D. 10:31 PM
Please see recordings of Part 1 of our conference at https://www.uclahealth.org/braintumor/patient-education


Al Musella 11:34 PM
Why do so many phase 3 trials fail after having success in phase 2?

Nghiemphu, Phioanh [Leia] M.D. 11:59 PM
There are inherent bias when enrolling in patients in small phase 2 trials, which is why therapies are usually not approved unless show efficacy in phase 3.


Brad Silver 12:30 AM
When was chemo changes from 21/7 for 2 years to 5/23 for 1 year?

Nghiemphu, Phioanh [Leia] M.D. 12:40 AM
This may have been addressed in part 1 of our conference. We never really used 21/7 dosing.


Brad Silver 12:31 AM
Does UCLA suggest clinical trials elsewhere for patients?

Nghiemphu, Phioanh [Leia] M.D. 12:40 AM
As best as we can but there are thousands out there and we usually refer patients to clinicaltrials.gov website.


Anonymous Attendee 12:47 AM
I have a few questions about this trial at UCLA: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
This trial with Merck’s Keytruda coupled with DC VAX L has been ongoing for about 14 months.
How many patients are enrolled to date?
Is there radiation or chemotherapy (temozolomide or avastin to help reduce swelling and prevent tumor growth)?
What has UCLA learned from this trial to date?
Can someone from the UK participate in this trial?
Why is the name of the vaccine “ATL-DC vaccine” and not DCVax-L? Are both generic the same?

Nghiemphu, Phioanh [Leia] M.D. 12:54 AM
As long as a patient can come to UCLA to have surgery for tumor resection and come to UCLA every 6 weeks for pembrolizumab or placebo infusion, they can be enrolled into this trial. It is ongoing and we are still enrolling patients. We do not have results as it is still too early. The vaccine names are different but it is the same vaccine.


Anonymous Attendee 12:54 AM
Are you aware of changing endpoints over the course of a clinical brain tumour trial here at UCLA? And must the participant be informed about a changed endpoint?

Nghiemphu, Phioanh [Leia] M.D. 12:57 AM
Most of our current trials do not always change endpoints. Participants would be informed if there are procedural changes to the trial because of the changed endpoints.


Anonymous Attendee 01:13 AM
As part of an industry-wide review, the FDA persuaded PD-1/L1 players Merck & Co., Bristol Myers Squibb, Roche and AstraZeneca to remove four indications on the labels of cancer drugs, after the failure of post-marketing studies.
The expert panel will discuss data on three indications for Merck’s Keytruda, two for Roche’s Tecentriq and one for Bristol Myers’ Opdivo.

Is that an issue for the ongoing combo trial keytruda and dcvax-l?

Nghiemphu, Phioanh [Leia] M.D. 01:19 AM
these treatments are supported by the clinical trial and not affected by the FDA panel which have to do with FDA provisional approvals. Neither vaccine nor pembrolizumab are indicated for brain cancer.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Recent NWBO News

Branded Legacy, Inc. Signs Joint Venture To Add Additional $300,000 a Year In Revenue BLEG Nov 23, 2022 11:10 AM

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial CMND Nov 23, 2022 9:50 AM

Branded Legacy, Inc. Gets Approval From State to Reduce Authorized Common Shares by 300 Million BLEG Nov 22, 2022 1:15 PM

Defiance Resumes Drilling In Zacatecas DNCVF Nov 22, 2022 11:53 AM

InnerScope Hearing Technologies (OTC: INND) Announces its HearingAssist Brand of OTC Hearing Aids on RiteAid.com INND Nov 22, 2022 11:52 AM

ECRID Offers Federal Housing Finance Agency (FHFA) Credit & Lending Platform to Immediately Assist Low-Credit and No-Credit Home Buyers, and Others ECDD Nov 22, 2022 11:51 AM

BioLife Sciences Inc. (OTC:PK BLFE) is Pleased to Announce Its Q1 2023 Slated Release of Its Copper-Infused Fabric Pot Prototype BLFE Nov 22, 2022 11:50 AM

Fission 3.0 Hits Off-Scale Radioactivity in New Discovery on PLN A1 Conductor FUU Nov 21, 2022 11:05 AM

Perpetual Industries Reports Strong Third-Quarter PRPI Nov 21, 2022 8:00 AM

Nextech AR Solutions Corp. Reports Record Q3 Sequential Growth As 3D Modeling Revenue Surges +192% and Gross Profit Margin Improves To +60% NEXCF Nov 17, 2022 7:03 PM

AgriFORCE Receives Notice of Allowance Related to its FORCEGH+ Facility from the United States Patent and Trademark Office AGRIW Nov 17, 2022 9:06 AM

Organicell Starts Enrolling Long COVID Trial OCEL Nov 17, 2022 8:38 AM

Mullen Announces Funding to Close on ELMS Assets MULN Nov 17, 2022 8:30 AM

Maison Luxe Reports Revenues of Approximately $3.7 Million for the Quarter Ended September 30, 2022 as Compared to Approximately $2.7 Million for the Quarter Ended September 30, 2021, an increase of over 35% MASN Nov 17, 2022 8:19 AM

SKYX Wins Consumer Electronics Show (CES) 2023 Innovation Award for Smart Home Category for Smart Sky Ceiling Plug SKYX Nov 17, 2022 8:07 AM